MedPath

Optical Guided Sentinel Node Biopsy for Staging of Vulvar Cancer (I)

Recruiting
Conditions
Sentinel Lymph Node
Vulvar Cancer
Registration Number
NCT06029504
Lead Sponsor
Rigshospitalet, Denmark
Brief Summary

The aim of this study is to investigate whether Sentinel Node biopsy can be performed without the use of lymphoscintigraphy and with ICG as a mono-tracer in women with vulvar cancer, unifocal tumor \< 4 cm (clinical stage IB and II). Further, to investigate the accuracy of combined PET-CT and ultrasound (US) of the groins with US-guided biopsy of suspicious lymph nodes for the identification of macro-metastases in women with vulvar cancer, unifocal tumor \< 4 cm.

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
Female
Target Recruitment
115
Inclusion Criteria
  • Patients with primary vulva cancer, FIGO stage IB (tumor < 4 cm)
  • Patients with unifocal recurrence in the vulva (tumor < 4 cm) located on the side where the patient is surgically naïve in the groin
Exclusion Criteria
  • Prior irradiation of the vulva or groins
  • Prior SNB or inguinal lymphadenectomy in the relevant groin
  • Known allergy to ICG or iodine (ICG contains 5% sodium iodine)

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Sentinel Node detection rateThree years

SN detection rate with ICG and 99mTc-Nanocoll alone perioperatively, where lymphoscintigraphy is blinded, in patients with vulvar cancer (tumor \< 4 cm) without clinical suspicion of metastases to the inguinal lymph nodes.

Secondary Outcome Measures
NameTimeMethod
Sensitivity, specificity, PPV and NPVThree years

Sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) of FDG PET-CT and US combined with US-guided biopsy of suspicious lymph nodes for the identification of macro-metastases in the groins

Trial Locations

Locations (1)

Copenhagen University Hospital

🇩🇰

Copenhagen, Denmark

© Copyright 2025. All Rights Reserved by MedPath